4/25/2013

The FDA granted breakthrough therapy status to Merck & Co.'s experimental antibody drug lambrolizumab as a treatment for advanced melanoma. Lambrolizumab, which targets the programmed death receptor, is also being evaluated as a treatment for nonsmall-cell lung cancer.

Full Story:
Fox Business

Related Summaries